TTFields Cancer Therapy Using IL11 Inhibition to Preserve Tumor Conductivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The application of Tumor Treating Fields (TTFields) can lead to increased IL11 expression in tumors, causing fibrosis and potentially decreasing the effectiveness of TTFields by lowering tumor conductivity.
Innovation Solution
Applying an alternating electric field with a frequency between 100 and 500 kHz to cancer cells, while inhibiting IL11 activity through methods such as decreasing IL11 expression or administering IL11 inhibitors, and optionally administering fibrosis inhibitors like sorafenib to maintain high tumor conductivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TTFields are applied to treat cancer, then cancer cell growth is inhibited, but IL11 expression increases causing fibrosis and decreasing tumor conductivity
Solution Approach 1:
The patent applies preliminary anti-action by administering IL11 inhibitors or fibrosis inhibitors before or during TTFields treatment to prevent the harmful fibrotic response. This preemptive approach blocks IL11 signaling pathways that would otherwise be activated by TTFields, thereby preventing the development of fibrosis and maintaining tumor conductivity throughout the treatment course.
Solution Approach 2:
The patent introduces intermediary substances (IL11 inhibitors, fibrosis inhibitors, or conductivity-enhancing agents) that mediate between the TTFields treatment and the tumor tissue. These intermediaries block the harmful signaling cascades initiated by IL11 expression while allowing the beneficial antitumor effects of TTFields to continue, thus decoupling the therapeutic benefit from the harmful side effect.
2Duration of action of stationary object
If TTFields treatment continues, then cancer cells are progressively inhibited, but fibrosis accumulates and reduces power loss density
Solution Approach 1:
The patent ensures continuity of useful action by maintaining effective TTFields treatment over extended periods while simultaneously administering inhibitors to prevent fibrosis accumulation. This dual approach allows the antitumor effects to continue accumulating without being interrupted by the development of fibrotic resistance, thereby sustaining both treatment duration and power loss density.
Solution Approach 2:
The patent applies parameter changes by dynamically adjusting treatment parameters (such as field intensity, frequency, or inhibitor dosage) in response to the evolving tumor microenvironment. This allows optimization of the balance between maintaining effective power loss density and preventing fibrosis-induced energy loss throughout the treatment course.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the efficacy of TTFields by preventing fibrosis-induced conductivity decreases in tumors, thereby maintaining high power loss density and treatment effectiveness.
Implementation Method 1
TTFields are low intensity (e.g., 1-3 V/cm) alternating electric fields within the intermediate frequency range (e.g., 100-500 kHz) that inhibit cancer cell growth
Implementation Method 2
This non-invasive treatment targets solid tumors
Data Source
AI summary
A reduction in viability of cancer cells (e.g., glioblastoma) and a reduction in tumor volume can be achieved by applying a 100-500 kHz (e.g., 200 kHz) alternating electric field to the cancer cells and inhibiting IL11 (interleukin-11) activity and optionally administering and anti-fibrotic agent. The inhibiting of IL11 activity may be accomplished, for example, by decreasing IL11 expression, inhibiting IL11 signaling, downregulating IL11, neutralizing IL11, blocking an IL11 receptor, administering an IL11 antagonist, administering an IL11 neutralizing antibody, or administering an IL11 receptor α (IL11Ra) neutralizing antibody.